Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Cash from Investing Activities (2017 - 2025)

Dianthus Therapeutics (DNTH) has 7 years of Cash from Investing Activities data on record, last reported at -$201.3 million in Q3 2025.

  • For Q3 2025, Cash from Investing Activities rose 22.4% year-over-year to -$201.3 million; the TTM value through Sep 2025 reached -$183.1 million, up 32.65%, while the annual FY2024 figure was -$286.8 million, 1516.15% down from the prior year.
  • Cash from Investing Activities reached -$201.3 million in Q3 2025 per DNTH's latest filing, down from $26.4 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $26.4 million in Q2 2025 and bottomed at -$259.4 million in Q3 2024.
  • Average Cash from Investing Activities over 4 years is -$32.4 million, with a median of -$6.9 million recorded in 2022.
  • Peak YoY movement for Cash from Investing Activities: soared 17048.84% in 2023, then crashed 2154.36% in 2024.
  • A 4-year view of Cash from Investing Activities shows it stood at -$12.7 million in 2022, then soared by 34.96% to -$8.2 million in 2023, then plummeted by 180.56% to -$23.1 million in 2024, then plummeted by 770.94% to -$201.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Investing Activities were -$201.3 million in Q3 2025, $26.4 million in Q2 2025, and $14.8 million in Q1 2025.